NTBL Notable Labs
- 0.760
- -0.014-1.81%
Notable Labs News
Notable Labs Unveils Strategic Outlook in Business Update
Express News | Chardan Capital Maintains Buy on Notable Labs, Lowers Price Target to $5
Buy Rating Affirmed for Notable Labs Amid Promising Drug Program and Robust PPMP Platform
Notable Labs | 10-Q: Quarterly report
Notable Labs to Participate in Fireside Chat at the Citizens JMP Securities Life Sciences Conference 2024
Fight Against Pancreatic Cancer Ramps Up as Market Size Revenues Expected to Exceed $36 Billion by 2036
The incidence of pancreatic cancer is increasing globally, which is driving the growth of the market. As of 2023, the American Cancer Society...
Tivic Health, RAPT Therapeutics, Notable Labs Among Healthcare Movers
Notable Labs Shares Strategic Insights in Business Overview
Express News | JMP Securities Reiterates Market Outperform on Notable Labs, Maintains $9 Price Target
Cisco To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Wells Farg
Express News | Notable Labs Ltd : Chardan Capital Markets Cuts Target Price to $7 From $9
Analysts Offer Insights on Healthcare Companies: Amgen (AMGN) and Notable Labs (NTBL)
Notable Labs Is Maintained at Buy by Chardan Capital
Notable Labs Is Maintained at Buy by Chardan Capital
Express News | Chardan Capital Maintains Buy on Notable Labs, Lowers Price Target to $7
Notable Labs Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/15/2024 493.22% Chardan Capital $9 → $7 Maintains Buy 12/19/2023 662.71% JMP Securities $13 → $9 Mainta
Buy Rating for Notable Labs: Financial Stability and Strategic Advances in AML Clinical Trials
Smaller Reporting Status for Notable Labs: Navigating Investor Concerns Amidst Scaled-Down Disclosure
Notable Labs Reports FY Results
Express News | Notable Labs Ltd: Current Cash Balance Is Sufficient to Support Its Planned Expenses, Obligations and Capital Expenditure Requirements Into Q4 2024.
Express News | Notable Labs Ltd: on Track to Significantly Advance Clinical Program for Volasertib in 2024
Analysis
Price Target
No Data
